AR083722A1 - Formas cristalinas de inhibidores de quinasas - Google Patents

Formas cristalinas de inhibidores de quinasas

Info

Publication number
AR083722A1
AR083722A1 ARP110101991A ARP110101991A AR083722A1 AR 083722 A1 AR083722 A1 AR 083722A1 AR P110101991 A ARP110101991 A AR P110101991A AR P110101991 A ARP110101991 A AR P110101991A AR 083722 A1 AR083722 A1 AR 083722A1
Authority
AR
Argentina
Prior art keywords
crystalline form
thieno
pyrazol
pyridin
fluorophenyl
Prior art date
Application number
ARP110101991A
Other languages
English (en)
Inventor
Geoff G Z Zhang
Paul J Brackemeyer
Ahmad Y Sheikh
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR083722A1 publication Critical patent/AR083722A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

N-(4-{4-amino-7-[1-(2-hidroxietil)-1H-pirazol-4-il]tieno[3,2-c]piridin-3-il}fenil)-N’-(3-fluorofenil)urea como base libre y formas cristalinas de la misma que son ingredientes farmacéuticos apropiados para hacer composiciones farmacéuticas útiles para el tratamiento de enfermedades, por ejemplo, cáncer. Proceso de obtención, composiciones farmacéuticas.Reivindicación 1: El compuesto N-(4-{4-amino-7-[1-(2-hidroxietil)-1H-pirazol-4-il]tieno[3,2-c]piridin-3-il}fenil)-N’-(3-fluorofenil)urea en una forma cristalina sólida, caracterizado porque la forma cristalina es la Forma I de la base libre, caracterizada por lo menos por un pico de difracción de rayos X en polvo en una o más cualesquiera de las siguientes posiciones: 7,20, 8,37, 11,38, 16,75, 16,95, 19,60, 22,04, y 22,86º 2q, ± 0,2º 2q. Reivindicación 13: El compuesto N-(4-{4-amino-7-[1-(2-hidroxietil)-1H-pirazol-4-il]tieno[3,2-c]piridin-3-il}fenil)-N’-(3-fluorofenil)urea en una forma cristalina sólida, caracterizado porque la forma cristalina es la base libre en la Forma II, caracterizada por lo menos por un pico de difracción de rayos X en polvo en una o más cualesquiera de las siguientes posiciones: 7,30, 8,81, 11,32, 15,08, 16,79, 19,46, 22,22, 22,70, 23,37, 24,29, 24,61, 25,07º 2q, ±@@@0,2º 2q.
ARP110101991A 2010-06-09 2011-06-09 Formas cristalinas de inhibidores de quinasas AR083722A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35305810P 2010-06-09 2010-06-09

Publications (1)

Publication Number Publication Date
AR083722A1 true AR083722A1 (es) 2013-03-20

Family

ID=44454740

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101991A AR083722A1 (es) 2010-06-09 2011-06-09 Formas cristalinas de inhibidores de quinasas

Country Status (18)

Country Link
US (2) US8357804B2 (es)
EP (1) EP2580219B1 (es)
JP (1) JP5711814B2 (es)
KR (1) KR20130112855A (es)
CN (1) CN103025741A (es)
AR (1) AR083722A1 (es)
AU (1) AU2011264899B2 (es)
BR (1) BR112012031469A2 (es)
CA (1) CA2802064A1 (es)
ES (1) ES2537708T3 (es)
HK (1) HK1182384A1 (es)
MX (1) MX2012014385A (es)
NZ (1) NZ605436A (es)
RU (1) RU2012157471A (es)
SG (1) SG186249A1 (es)
TW (1) TWI492949B (es)
WO (1) WO2011156461A1 (es)
ZA (1) ZA201209647B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202110406SA (en) 2019-04-11 2021-10-28 Angion Biomedica Corp Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026944A1 (en) * 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
GB0402518D0 (en) * 2004-02-05 2004-03-10 Astrazeneca Ab Therapeutic agents
US20070135387A1 (en) * 2005-12-08 2007-06-14 Michaelides Michael R Inhibitors of protein kinases
EP2262815A4 (en) * 2008-03-05 2012-04-11 Methylgene Inc Inhibitors of protein intolerance activity
TWI441827B (zh) 2008-12-05 2014-06-21 Abbvie Bahamas Ltd 具改良ｃｙｐ安全性之激酶抑制劑

Also Published As

Publication number Publication date
TW201204736A (en) 2012-02-01
US8357804B2 (en) 2013-01-22
CN103025741A (zh) 2013-04-03
RU2012157471A (ru) 2014-07-20
WO2011156461A1 (en) 2011-12-15
EP2580219B1 (en) 2015-02-25
US20120149726A1 (en) 2012-06-14
MX2012014385A (es) 2013-05-01
ES2537708T3 (es) 2015-06-11
SG186249A1 (en) 2013-01-30
CA2802064A1 (en) 2011-12-15
NZ605436A (en) 2014-11-28
JP5711814B2 (ja) 2015-05-07
AU2011264899B2 (en) 2015-01-22
BR112012031469A2 (pt) 2016-11-01
US8592589B2 (en) 2013-11-26
KR20130112855A (ko) 2013-10-14
HK1182384A1 (en) 2013-11-29
JP2013528220A (ja) 2013-07-08
EP2580219A1 (en) 2013-04-17
AU2011264899A1 (en) 2013-01-10
TWI492949B (zh) 2015-07-21
US20130136804A1 (en) 2013-05-30
ZA201209647B (en) 2014-02-26

Similar Documents

Publication Publication Date Title
ECSP19011216A (es) Inhibidores de piridopyrimdinona cdk2/4/6
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
MX2013004491A (es) Boronatos como inhibidores de arginasa.
UY33476A (es) Estimuladores de sgc
AR096758A1 (es) Inhibidores cristalinos de bromodominios
SA515360229B1 (ar) مثبطات‎ ‎عامل التمايز والنمو 8‏
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
CL2012000059A1 (es) Compuestos derivados de pirazolo[1,5-a]pirimidina; proceso de preparacion; composicion farmaceutica que los comprende; y su uso como inhbidores de trk-quinasa para el tratamiento de enfermedades o trastornos tales como dolor, cancer, inflamacion; entre otras.
BRPI0818893B8 (pt) compostos de tropano, suas composições farmacêuticas, seus usos e método in vitro de inibição de hsp90 em uma célula
CO6450612A2 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
UY35991A (es) Bencimidazol-2-aminas como inhibidores de midh1
UY31068A1 (es) Ligandos purinoreceptores p2x, metodos para la prparacion de los mismos, composiciones farmaceuticas que los contienen y sus usos 570
MX348422B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
CR20130213A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogènesis
CR20140216A (es) 5,7-imidazo[1,2-c]pirimidinas sustituidas
UA115320C2 (uk) Інгібітори кінази
NI200700311A (es) Derivados de tienopirimidina y tienopiridina como inhibidores de la cinasa de flt-3
MX2013002329A (es) Agonista de receptores de neutrofina y sus usos como medicamentos.
BRPI0916566B8 (pt) isonicotinamida fenilamina, seu uso, composição farmacêutica, e kit
MX2015008187A (es) Inhibidores de alk deuterados.
MX2012014386A (es) Formas cristalinas de inhibidores de cinasa.
UY31672A1 (es) "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación"
AR090209A1 (es) Polimorfos de 1-(3-terc-butil-1-p-tolil-1h-pirazol-5-il)-3-(5-fluoro-2-(1-(2-hidroxietil)-1h-indazol-5-iloxi)bencil)urea y composiciones farmaceuticas que los comprenden
AR083722A1 (es) Formas cristalinas de inhibidores de quinasas
AR083152A1 (es) Formas cristalinas de inhibidores de quinasas

Legal Events

Date Code Title Description
FB Suspension of granting procedure